Global Interleukin Inhibitors Market - 2021-2028
The global interleukin inhibitors market size was valued US$ XX billion in 2019 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).
Interleukin inhibitors are immunosuppressive agents that inhibit interleukins' action, synthesized by monocytes, macrophages, lymphocytes, and certain other cells. These interleukin inhibitors are used to treat autoimmune and inflammatory disorders such as psoriasis, psoriatic arthritis, rheumatoid arthritis, asthma, and inflammatory bowel disease.
The interleukin inhibitors market growth is driven by the increase in the prevalence of chronic inflammatory diseases such as arthritis, psoriasis, and asthma and increasing global prevalence of autoimmune disorders, and rising geriatric population, and technological advancements in developing novel interleukin inhibitors.
Increase in the prevalence of chronic inflammatory diseases such as arthritis, psoriasis, and asthma, is expected to drive the growth in the forecast period
According to the Centers for Disease Control and Prevention (CDC) report, in 2018, around 7.9% of the United States population had asthma. Asthma is more common among females and children aged 5 to 14 years. In children, the prevalence rate was 7.5%, and in adults, 7.7%. Moreover, currently available interleukin-based treatments are very effective at controlling asthma in the majority of patients. For instance, GlaxoSmithKline Plc offers Nucala, a humanized, interleukin-5 (IL-5) antagonist monoclonal antibody used to treat severe eosinophilic asthma. Thus, due to the factors mentioned above, it is expected to drive market growth over the forecast period.
High costs associated with biological therapy is likely to hamper the market growth
High costs associated with biological therapy are hampering the interleukin inhibitors market. Biologic treatment that has revolutionized the care of psoriasis patients is expensive than the other treatments. The total annual cost ranged from $2,077 to the US $13,132 for psoriasis and from $10,924 to $17,050 for psoriatic arthritis per patient. As of 2020, biologics treatment cost was around $10,000 to $30,000 per year. Therefore, the higher price of biologics and low healthcare expenditure in developing countries will likely restrict the market growth.
COVID-19 Impact Analysis
Following the COVID-19 outbreak in December 2019, the disease has spread to over 100 countries globally, and the World Health Organization has declared it a public health emergency. According to the World Health Organization’s report, the coronavirus (COVID-19) manifestation has resulted in more than 52.7 million infected individuals worldwide as of November 13, 2020.
COVID-19 has affected every market globally and has also impacted the global acetophenone market in the following ways; by directly affecting production and demand, creating disruptions in distribution channels, and its financial impact on firms and financial markets.
As a result, the impact of the COVID-19 pandemic is also expected to decrease the growth of the market.
The IL-23 segment is expected to hold largest share in this market segment
IL-23 dominated the interleukin inhibitor types, largely driven by the blockbuster drug Stelara. Recent additions were made to the segment of Tremfya in 2017, Ilumya in 2018, and Skyrizi in 2019. Although Stelara continues to generate high revenue despite nearing patent expiry in 2023, the IL-23 segment is anticipated to witness strong growth driven by the anticipated new entrants. For instance, as per the annual report of Johnson & Johnson, Stelara hit $6.62 billion in sales in 2019.
The psoriasis segment is expected to hold largest share in this market segment
Psoriasis is one of the most common chronic skin diseases, which is likely to increase with age. The major factors driving the psoriasis segment growth include increasing disease prevalence, growing consumer awareness, and favorable reimbursement policies. Some of the effective FDA-approved interleukin inhibitors for psoriasis treatment include Stelara, Cosentyx, Siliq and Taltz.
According to the International Federation of Psoriasis Associations 2020, estimates that more than 125 million people around the world have psoriasis. In addition, people living with psoriasis have an increased risk of co-morbidities such as diabetes and cardiovascular disease. The impact on mental health can also be significant. To prevent such co-morbidities associated with psoriasis is likely to increase demand for interleukin inhibitors over the forecast period.
In addition, in 2020, UCB announced that U.S Food and Drug Administration (FDA) had accepted the Biologics License Application (BLA) for bimekizumab (UCB) for the treatment of moderate to severe plaque psoriasis in adults. Thus, owing to the factors mentioned above, it is expected to drive market growth in the near future.
The hospital pharmacies segment is expected to hold largest share in this market segment
The hospital pharmacies held the largest share in the interleukin inhibitors market. This is mainly owing to increasing number of patients suffering from conditions which are treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, growing number of hospitals along with adequate reimbursement policies is also contributing to the growth of this segment. For instance, according to the World Psoriasis Day consortium, globally, 125 million people, more than 3% of the total population, have psoriasis. In addition, according to the National Psoriasis Foundation, more than 8 million Americans have psoriasis. Hence, the rising disease burden and demand for proper medicines are some of the factors supporting the segmental growth of the market.
North America region holds the largest market share of global interleukin inhibitors market
In the North American region, the United States is expected to hold significant market share due to major market players, increasing research and development activities in developing novel products, proactive government initiatives and an increase in healthcare expenditure.
Factors such as key pipeline products and label expansions of existing products indicated for psoriatic arthritis, Crohn’s disease, and ulcerative colitis are key growth propellers. According to the National Clinical Trial (NCT) Registry, as of December 2020, there are more than 200 ongoing clinical trials related to interleukin inhibitors in the United States across different phases of development for various indications. Thus, owing to the factors mentioned above, the United States market is expected to be one of the largest and expected to grow.
The global interleukin inhibitors market is sightly competitive with presence of global companies. Some of the key players which are contributing to the growth of the market include Johnson and Johnson, Novartis AG, AbbVie Inc, Eli Lilly and Company, AstraZeneca Plc, Sun Pharmaceutical Industries Limited, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Teva Pharmaceuticals Industries, Ltd, Sanofi SA, Shenzhen Nexconn Pharmatechs Ltd, Hangzhou FandaChem Co. Ltd, Career Henan Chemical Co, Shanghai Minbiotech Co., Ltd. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally. For instance, in 2018, Sun Pharmaceutical introduced Ilumya (tildrakizumab-asmn) to treat the plaque psoriasis (moderate-to-severe).
Interleukin Inhibitors Market Key Companies to Watch
Overview: Eli Lilly is an American pharmaceutical company was founded in 1876 by Colonel Eli Lilly, Headquarters located in Indianapolis, Indiana, U.S.A with more than 34,000 employees worldwide. Approximately 8,000 employees engaged in research and development and clinical research conducted in more than 55 countries with Research and development facilities located in 7 countries, Manufacturing plants located in 7 countries and Products marketed in 120 countries.
Product Portfolio: The Company’s portfolio comprised of include Covid-19, Diabetes, Cancer, Immunology, Pain, Neurodegeneration.
Key Development: Eli Lilly and Company developing Lebrikizumab"" is a monoclonal antibody designed to bind IL-13 with very high affinity inhibiting the biological effects of IL-13. It is under phase 3 trials for the treatment of moderate-to-severe atopic dermatitis.
Why Purchase the Report?
• Visualize the composition of the interleukin inhibitors market segmentation by type, application, distribution channel and region highlighting the key commercial assets and players.
• Identify commercial opportunities in interleukin inhibitors market by analyzing trends and co-development deals.
• Excel data sheet with thousands of data points of interleukin inhibitors market - level 4/5 segmentation.
• PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
• Product mapping in excel for the key product of all major market players
The global interleukin inhibitors market report would provide an access to an approx. 61 market data table, 56 figures and 200 pages.
• Service Providers/ Buyers
• Industry Investors/Investment Bankers
• Education & Research Institutes
• Research Professionals
• Emerging Companies
Global Interleukin Inhibitors Market - By Type
• Other types
Global Interleukin Inhibitors Market – By Application
• Inflammatory Bowel Disease (IBD)
• Other Applications
Global Interleukin Inhibitors Market – By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
Global Interleukin Inhibitors Market - By Region
• North America
• Middle East & Africa
• South America
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook